Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Capital Expenditures (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Capital Expenditures for 16 consecutive years, with $430000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 79.56% to $430000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 30.1% decrease, with the full-year FY2024 number at $4.1 million, up 182.49% from a year prior.
  • Capital Expenditures was $430000.0 for Q3 2025 at Xtant Medical Holdings, up from $366000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.1 million in Q3 2024 to a low of $223000.0 in Q3 2023.
  • A 5-year average of $601842.1 and a median of $484000.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 843.5% in 2024, then tumbled 79.56% in 2025.
  • Xtant Medical Holdings' Capital Expenditures stood at $626000.0 in 2021, then decreased by 29.23% to $443000.0 in 2022, then fell by 18.06% to $363000.0 in 2023, then skyrocketed by 85.12% to $672000.0 in 2024, then plummeted by 36.01% to $430000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Capital Expenditures are $430000.0 (Q3 2025), $366000.0 (Q2 2025), and $1.2 million (Q1 2025).